Literature DB >> 33032171

Hypothesis: Oxytocin is a direct COVID-19 antiviral.

Phuoc-Tan Diep1, Khojasta Talash2, Violet Kasabri3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33032171      PMCID: PMC7528823          DOI: 10.1016/j.mehy.2020.110329

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


× No keyword cloud information.
A recent Correspondence proposed the neurohormone oxytocin as a defence for COVID-19 [1]. This is one of a handful of papers in the academic literature [2], [3], [4] providing patterns and mechanisms to support oxytocin as an intervention for COVID-19. We propose an additional arrow in the quiver of oxytocin's non-classical functions. Our hypothesis is that oxytocin may have direct antiviral effects against SARS-CoV-2. Dipeptidyl peptidase-4 (DPP4) protease inhibitors have been proposed as a treatment for Middle Eastern respiratory syndrome coronavirus and COVID-19 [5] and oxytocin happens to be a natural DPP4 inhibitor [6], therefore it is not unreasonable to propose that oxytocin could inhibit other proteases. There are three papers that raise the possibility that oxytocin could be an antiviral against SARS-CoV-2 via other targets. The first two papers [7], [8] identify oxytocin as one of the FDA drugs that could inhibit the SARS-CoV-2 main protease. The third paper [9] raises the possibility that oxytocin analogues, an oxytocin antagonist and a vasopressin analogue are inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. We suggest that this raises the possibility that oxytocin, with its similar structure, could also be an inhibitor of some of these enzymes. Future research is needed to confirm if oxytocin is a direct antiviral via inhibition of the SARS-CoV-2 main protease, other viral targets or if it inhibits transmembrane serine protease 2 (TMPRSS2) for instance. Even if oxytocin does not have direct antiviral effects it still has sufficient mechanisms that could make it effective against COVID-19 such as immunomodulatory, cardioprotective, anti-diabetic and anabolic functions as well as psycho-social functions [10]. Increasing endogenous oxytocin could increase viral resistance and increase general health especially in vulnerable population groups. Oxytocin can be administered as an exogenous drug in multiple ways; however, oxytocin in solution requires consistent refrigeration. The more recent development of a dry inhaler makes oxytocin available to the whole world. Therefore, if oxytocin is identified as a true antiviral it would make oxytocin the single most effective defence and treatment for COVID-19, helping us turn the tide in this global war and helping us stop the Second Wave that threatens to overwhelm us. Oxytocin may be the Achilles heel of a seemingly invulnerable enemy.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  6 in total

Review 1.  Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19.

Authors:  Stephani C Wang; Fengmin Zhang; Hui Zhu; Haipeng Yang; Yang Liu; Ping Wang; Vladimir Parpura; Yu-Feng Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

Review 2.  COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?

Authors:  Renata Novak Kujundžić
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

3.  TRPV1, Nrf2, and COVID-19: Could Oxytocin Have a Beneficial Role to Play?

Authors:  Phuoc-Tan Diep
Journal:  Int Arch Allergy Immunol       Date:  2022-01-03       Impact factor: 2.749

4.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

Review 5.  Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection.

Authors:  Jose M Adrover; Lucia Carrau; Juliane Daßler-Plenker; Yaron Bram; Vasuretha Chandar; Sean Houghton; David Redmond; Joseph R Merrill; Margaret Shevik; Benjamin R tenOever; Scott K Lyons; Robert E Schwartz; Mikala Egeblad
Journal:  JCI Insight       Date:  2022-03-08

6.  Paradoxical low severity of COVID-19 in Prader-Willi syndrome: data from a French survey on 647 patients.

Authors:  Muriel Coupaye; Virginie Laurier; Grégoire Benvegnu; Christine Poitou; Pauline Faucher; Héléna Mosbah; Gwenaelle Diene; Graziella Pinto; Laura González Briceño; Christine Merrien; Ana Camarena Toyos; Emilie Montastier; Maithé Tauber; Fabien Mourre
Journal:  Orphanet J Rare Dis       Date:  2021-07-21       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.